

Anne Lindebo Holm Øvrehus  
Infektionsmedicinsk afdeling Q,  
Odense Universitetshospital  
Danmark  
E-mail: anne.oevrehus@rsyd.dk

## Publikationer

### **High hepatitis c treatment uptake in substance use treatment centers after an intervention with implementation of dried blood spot testing and decentralized treatment**

Dröse, S., Christensen, P. B., Holm, D. K., Røge, B., Hansen, J. F., Madsen, L. W. & Øvrehus, A. L. H., okt. 2024. 1 s.

### **Effect of direct-acting antivirals on the titers of human pegivirus 1 during treatment of chronic hepatitis C patients**

Fahnøe, U., Madsen, L. W., Christensen, P. B., Sølund, C. S., Møllerup, S., Pinholt, M., Weis, N., Øvrehus, A. & Bukh, J., sep. 2024, I: Microbiology Spectrum. 12, 9, 14 s., e00641-24.

### **Combining cross-sectional survey and register data improved the estimate of hepatitis C prevalence among patients attending a psychiatric emergency department in Denmark**

Rose, T. V., Christensen, P. B., Hjorth, P., Madsen, L. W., Hansen, J. F., Dröse, S., Harvald, G. B., Røge, B. T. & Øvrehus, A. L. H., apr. 2024, I: Infectious Diseases. 56, 4, s. 277-284

### **Use of molnupiravir: A Danish nationwide drug utilization study**

Ladebo, L., Rasmussen, L., Jensen, P. B., Lindahl, M., Øvrehus, A., Hallas, J. & Reilev, M., jan. 2024, I: Pharmacoepidemiology and Drug Safety. 33, 1, 6 s., e5700.

### **Full-length sequence analysis of hepatitis C virus genotype 3b strains and development of an in vivo infectious 3b cDNA clone**

Bajpai, P. S., Collignon, L., Sølund, C., Madsen, L. W., Christensen, P. B., Øvrehus, A. L. H., Weis, N., Holmbeck, K., Fahnøe, U. & Bukh, J., 21. dec. 2023, I: Journal of Virology. 97, 12, e0092523.

### **Hepatitis C screening and linkage to care with a mobile clinic in Southern Denmark**

Dröse, S., Øvrehus, A. L. H., Holm, D. K., Røge, B. T. & Christensen, P. B., nov. 2023, I: International Journal of Drug Policy. 121, 5 s., 104180.

### **Peer-delivered point-of-care testing and linkage to treatment for hepatitis C virus infection among marginalized populations through a mobile clinic in Copenhagen, Denmark**

Demant, J., Krohn-Dehli, L., Van der Veen, J., Øvrehus, A., Lazarus, J. V. & Weis, N., nov. 2023, I: International Journal of Drug Policy. 121, 8 s., 104185.

### **Testing and linkage to care for viral hepatitis in patients admitted for psychiatric care**

Dröse, S., Skovmand, L., Barkanyi, Z., Holm, D. K., Christensen, P. B. & Øvrehus, A. L. H., 17. okt. 2023. 1 s.

### **Experience with Sotrovimab treatment of SARS-CoV-2 infected patients in Denmark**

Rasmussen, L. D., Lebech, A.-M., Øvrehus, A., Poulsen, B. K., Christensen, H. R., Nielsen, H., Johansen, I. S., Omland, L. H., Wiese, L., Helleberg, M., Storgaard, M., Dalager-Pedersen, M., Rasmussen, T. A., Benfield, T., Petersen, T. S., Andersen, Å. B., Gram, M. A., Stegger, M., Edslev, S. M. & Obel, N., jun. 2023, I: British Journal of Clinical Pharmacology. 89, 6, s. 1820-1833

### **Retrieval of patients with hepatitis C who were lost to follow-up in Southern Denmark**

Dröse, S., Hansen, J. F., Røge, B. T., Øvrehus, A. L. H. & Christensen, P. B., maj 2023, I: Infectious Diseases. 55, 5, s. 361-369

### **Senfølger af COVID-19 – status og udfordringer**

Sørensen, A. I. V., Øvrehus, A. L. H., Hviid, A., Koch, A., Tankisi, H., Ullum, H., Agergaard, J., Mølgaard Christiansen, K., Busborg Jørgensen, M., Gubbels, S., Leth, S. & Krause, T. G., 3. apr. 2023, I: Ugeskrift for Læger. 185, 7, s. 648-649

### **Hepatitis C time trends in reported cases and estimates of the hidden population born before 1965, Denmark and Sweden, 1990 to 2020**

Christensen, P. B., Debrabant, B., Cowan, S., Debrabant, K., Øvrehus, A. L. H. & Duberg, A.-S., 15. dec. 2022, I: *Eurosurveillance*. 27, 50, 9 s., 2200243.

### **A multinational Delphi consensus to end the COVID-19 public health threat**

Lazarus, J. V., Romero, D., Kopka, C. J., Karim, S. A., Abu-Raddad, L. J., Almeida, G., Baptista-Leite, R., Barocas, J. A., Barreto, M. L., Bar-Yam, Y., Bassat, Q., Batista, C., Bazilian, M., Chiou, S. T., del Rio, C., Dore, G. J., Gao, G. F., Gostin, L. O., Hellard, M. & Jimenez, J. L. & 31 flere, Kang, G., Lee, N., Maticič, M., McKee, M., Nsanzimana, S., Oliu-Barton, M., Pradelski, B., Pyzik, O., Rabin, K., Raina, S., Rashid, S. F., Rathe, M., Saenz, R., Singh, S., Trock-Hempler, M., Villapol, S., Yap, P., Binagwaho, A., Kamarulzaman, A., El-Mohandes, A., Barreto, M., del Rio, C., Abdulla, S., Addleman, S., Aghayeva, G., Agius, R., Ahmed, M., Cheng, K. K., Kristensen, F., Øvrehus, A. & The COVID-19 Consensus Statement Panel, 10. nov. 2022, I: *Nature*. 611, 7935, s. 332-345

### **Levels of SARS-CoV-2 antibodies among fully vaccinated individuals with Delta or Omicron variant breakthrough infections**

Stærke, N. B., Reekie, J., Nielsen, H., Benfield, T., Wiese, L., Knudsen, L. S., Iversen, M. B., Iversen, K., Fogh, K., Bodilsen, J., Juhl, M. R., Lindvig, S. O., Øvrehus, A., Madsen, L. W., Kjastrup, V., Andersen, S. D., Juhl, A. K., Andreassen, S. R., Ostrowski, S. R. & Erikstrup, C. & 6 flere, Fischer, T. K., Tolstrup, M., Østergaard, L., Johansen, I. S., Lundgren, J. & Sogaard, O. S., 1. aug. 2022, I: *Nature Communications*. 13, 8 s., 4466.

### **Characteristics Associated with Serological Covid-19 Vaccine Response and Durability in an Older Population with Significant Comorbidity: The Danish Nationwide ENFORCE Study**

Sogaard, O. S., Reekie, J., Johansen, I. S., Nielsen, H., Benfield, T., Wiese, L., Stærke, N. B., Iversen, K., Fogh, K., Bodilsen, J., Iversen, M., Knudsen, L. S., Kjastrup, V., Larsen, F. D., Andersen, S. D., Hvidt, A. K., Andreassen, S. R., Madsen, L. W., Lindvig, S. O. & Øvrehus, A. & 11 flere, Ostrowski, S. R., Abildgaard, C., Matthews, C., Jensen, T. O., Raben, D., Erikstrup, C., Fischer, T. K., Tolstrup, M., Østergaard, L., Lundgren, J. & on behalf of the ENFORCE Writing Group, aug. 2022, I: *Clinical Microbiology and Infection*. 28, 8, s. 1126-1133

### **Screening for hepatitis C in Denmark- the effect of a mobile outreach intervention**

Dröse, S., Madsen, L. W., Harvald, G. B., Grinderslev, S., Kofoed, K., Kræmer, L., Øvrehus, A. L. H. & Christensen, P. B., 1. jul. 2022, I: *Journal of Hepatology*. 77, Suppl. 1, s. S550

### **Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study**

Blach, S., Terrault, N. A., Tacke, F., Gamkrelidze, I., Craxi, A., Tanaka, J., Waked, I., Dore, G. J., Abbas, Z., Abdallah, A. R., Abdulla, M., Aghemo, A., Aho, I., Akarca, U. S., Alalwan, A. M., Alanko Blomé, M., Al-Busafi, S. A., Aleman, S., Alghamdi, A. S. & Al-Hamoudi, W. K. & 31 flere, Aljumah, A. A., Al-Naamani, K., Al Serkal, Y. M., Altraif, I. H., Anand, A. C., Anderson, M., Andersson, M. I., Athanasakis, K., Baatarkhuu, O., Bakieva, S. R., Ben-Ari, Z., Bessone, F., Biondi, M. J., Bizri, A. R. N., Brandão-Mello, C. E., Brigida, K., Brown, K. A., Brown, R. S., Bruggmann, P., Brunetto, M. R., Busschots, D., Buti, M., Butsashvili, M., Cabezas, J., Chae, C., Chaloska Ivanova, V., Chan, H. L. Y., Cheinquer, H., Christensen, P. B., Øvrehus, A. L. & The Polaris Observatory HCV Collaborators, maj 2022, I: *The Lancet Gastroenterology & Hepatology*. 7, 5, s. 396-415

### **Four Weeks Treatment with Glecaprevir/Pibrentasvir + Ribavirin-A Randomized Controlled Clinical Trial**

Madsen, L. W., Christensen, P. B., Hansen, J. F., Røge, B. T., Holm, D. K., Dröse, S. & Øvrehus, A., 16. mar. 2022, I: *Viruses*. 14, 3, 614.

### **A multi-level intervention to eliminate hepatitis C from the Region of Southern Denmark: the C-Free-South project**

Dröse, S., Øvrehus, A. L. H., Holm, D. K., Madsen, L. W., Mössner, B. K., Sørholm, J., Hansen, J. F., Røge, B. T. & Christensen, P. B., 1. mar. 2022, I: *BMC Infectious Diseases*. 22, 202.

### **Immunological Characteristics of Patients Receiving Ultra-Short Treatment for Chronic Hepatitis C**

Madsen, L. W., Christensen, P. B., Øvrehus, A., Bryde, D. M. S., Holm, D. K., Lillevang, S. T. & Nielsen, C., 2022, I: *Frontiers in Cellular and Infection Microbiology*. 12, 8 s., 885824.

### **Screening for hepatitis C in Denmark- the effect of a mobile outreach intervention**

Dröse, S., Madsen, L. W., Harvald, G. B., Grinderslev, S., Kofoed, K., Kræmer, L., Øvrehus, A. L. H. & Christensen, P. B., 2022. 1 s.

### **Fra behandling i blinde mod elimination af hepatitis C**

Christensen, P. B., Søholm, J. & Øvrehus, A. L. H., 15. nov. 2021, I: Ugeskrift for Læger. 183, 22, V02210145.

### **Inferior cure rate in pilot study of 4-week glecaprevir/pibrentasvir treatment with or without ribavirin of chronic hepatitis C**

Wulff Madsen, L., Brehm Christensen, P., Fahnøe, U., Pedersen, M. S., Bukh, J. & Øvrehus, A., nov. 2021, I: Liver International. 41, 11, s. 2601-2610

### **Characterization of a Novel Hepatitis C Virus Genotype 1 Subtype from a Patient Failing 4 Weeks of Glecaprevir-Pibrentasvir Treatment**

Pedersen, M. S., Fahnøe, U., Madsen, L. W., Christensen, P. B., Øvrehus, A. & Bukh, J., 14. okt. 2021, I: Microbiology Resource Announcements. 10, 41, :e00755-21.

### **BASELINE CAPABILITY FOR HEPATITIS TEST AND TREATMENT IN DRUG TREATMENT CLINICS IN THE REGION OF SOUTHERN DENMARK- A PRE-ELIMINATION INTERVENTION ASSESSMENT**

Dröse, S., Christensen, P. B., Holm, D. K., Røge, B. T. & Øvrehus, A. L. H., okt. 2021.

### **Emergency department testing is feasible but ineffective to eliminate hepatitis C in Denmark**

Wentworth, J. J., Øvrehus, A. L. H., Hansen, J. F., Biesenbach, P. & Christensen, P. B., 12. aug. 2021, I: Infectious Diseases. 53, 12, s. 930-941

### **Hepatitis C standards of care: A review of good practices since the advent of direct-acting antiviral therapy**

Lazarus, J. V., Picchio, C. A., Guy, D., Aleman, S., James, C., Nava, F. A., Øvrehus, A., Turnes, J., Ward, J. W. & Ustianowski, A., mar. 2021, I: Clinics and Research in Hepatology and Gastroenterology. 45, 2, 101564.

### **Comparison of six commercially available SARS-CoV-2 antibody assays - choice of assay depends on intended use**

Nilsson, A. C., Holm, D. K., Justesen, U. S., Gorm-Jensen, T., Andersen, N. S., Øvrehus, A., Johansen, I. S., Michelsen, J., Sprogøe, U. & Lillevang, S. T., feb. 2021, I: International Journal of Infectious Diseases. 103, s. 381-388

### **Low mortality of hospitalised patients with COVID-19 in a tertiary Danish hospital setting**

Madsen, L. W., Lindvig, S. O., Rasmussen, L. D., Knudtzen, F. C., Laursen, C. B., Øvrehus, A., Nielsen, S. L. & Johansen, I. S., jan. 2021, I: International Journal of Infectious Diseases. 102, s. 212-219

### **The case for simplifying and using absolute targets for viral hepatitis elimination goals**

Polaris Observatory Collaborators, Christensen, P. B. (Medlem af forfattergruppering) & Øvrehus, A. L. H. (Medlem af forfattergruppering), jan. 2021, I: Journal of Viral Hepatitis. 28, 1, s. 12-19

### **Baseline capability for hepatitis c test and treatment in drug treatment clinics in the Region of Southern Denmark. A pre-elimination intervention assessment**

Dröse, S., Christensen, P. B., Holm, D. K., Røge, B. T. & Øvrehus, A. L. H., 2021.

### **Low incidence of HCC in chronic hepatitis C patients with pretreatment liver stiffness measurements below 17.5 kilopascal who achieve SVR following DAAs**

Søholm, J., Hansen, J. F., Mössner, B., Røge, B. T., Lauersen, A., Hansen, J. B., Weis, N., Barfod, T. S., Lunding, S., Øvrehus, A., Mohey, R., Thielsen, P. & Christensen, P. B., 10. dec. 2020, I: PLOS ONE. 15, 12, 17 s., e0243725.

### **The Copenhagen test and treat hepatitis C in a mobile clinic study: A protocol for an intervention study to enhance the HCV cascade of care for people who inject drugs (T'N'T HepC)**

Lazarus, J. V., Øvrehus, A., Demant, J., Krohn-Dehli, L. & Weis, N., 9. nov. 2020, I: BMJ Open. 10, 11, 7 s., e039724.

### **Hepatitis C prevalence in Denmark in 2016—An updated estimate using multiple national registers**

Nielsen, S., Hansen, J. F., Hay, G., Cowan, S., Jepsen, P., Omland, L. H., Krarup, H. B., Søholm, J., Lazarus, J. V., Weis, N., Øvrehus, A. & Christensen, P. B., sep. 2020, I: PLOS ONE. 15, 9, 12 s., e0238203.

**A MULTI-LEVEL INTERVENTION TO ELIMINATE HEPATITIS C FROM THE REGION OF SOUTHERN DENMARK. THE C-FREE SOUTH STRATEGY**

Dröse, S., Øvrehus, A. L. H., Holm, D. K., Wulff Madsen, L., Mössner, B., Fuglsang Hansen, J., Søholm, J., Røge, B. T. & Christensen, P. B., nov. 2019.

**A multi-level intervention to eliminate hepatitis c from the region of southern denmark. The c-free south strategy**

Drose, S., Ovrehus, A., Holm, D. K., Madsen, L. W., Mossner, B. K., Soholm, J., Hansen, J. F., Hansen, S., Ramskov, B., Roge, B. T. & Christensen, P. B., okt. 2019, I: *Hepatology*. 70, Suppl. 1, s. 944A-945A 1567.

**A model of care for people attending drug treatment centers aiming at hepatitis C elimination by 2022. A part of the C-FREE SOUTH STRATEGY**

Dröse, S., Øvrehus, A. L. H., Holm, D. K., Røge, B. T., Lillevang, S. T. & Christensen, P. B., 12. sep. 2019.

**Risk behaviours and prevalence of blood borne infections in young people seeking treatment or advice for drug use - the potential of dried blood spots**

Øvrehus, A. L. H., Blunck, H., Lassen, H., Holm, D. K., Søholm, J., Skamling, M. & Christensen, P. B., 11. sep. 2019.

**How can we achieve WHO's elimination target for hepatitis C incidence?**

Øvrehus, A. L. H. & Midgard, H., jun. 2019, I: *The Lancet Gastroenterology & Hepatology*. 4, 6, s. 415-417

**Screening for technical flaws in multiple-choice items: A generalizability study**

Dyrberg O'Neill, L., Radl Mortensen, S. M., Nørgaard, C., Holm, A. L. & Friis, U. G., 1. apr. 2019, I: *Dansk Universitetspædagogisk Tidsskrift*. 14, 26, s. 51-65

**4 week treatment for hepatitis C: A randomized controlled trial (4RIBC)**

Wulff Madsen, L., Øvrehus, A. L. H., Gerstoft, J., Weis, N., Barfod, T. S., Laursen, A. L., Krarup, H., Ernst, A. & Christensen, P. B., apr. 2019, I: *Journal of Hepatology*. 70, 1 Suppl., s. e247-e248 THU-193.

**Test uptake and Hepatitis C prevalence in 5483 Danish people in drug use treatment from 1996 to 2015: a registry-based cohort study**

Øvrehus, A., Nielsen, S., Hansen, J. F., Holm, D. K. & Christensen, P., mar. 2019, I: *Addiction*. 114, 3, s. 494-503

**Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework**

Day, E., Hellard, M., Treloar, C., Bruneau, J., Martin, N. K., Øvrehus, A., Dalgard, O., Lloyd, A., Dillon, J., Hickman, M., Byrne, J., Litwin, A., Maticic, M., Bruggmann, P., Midgard, H., Norton, B., Trooskin, S., Lazarus, J. V., Grebely, J. & International Network on Hepatitis in Substance Users (INHSU), jan. 2019, I: *Liver International*. 39, 1, s. 20-30

**Towards Elimination of Hepatitis C**

Øvrehus, A. L. H., 2019, Odense: Syddansk Universitet. Det Sundhedsvidenskabelige Fakultet.

**HCV treatment for people with recent drug use: time for new measures of success?**

Øvrehus, A. & Kåberg, M., 1. nov. 2018, I: *The Lancet Gastroenterology & Hepatology*. 3, 11, s. 731-732 2 s.

**Screening for flawed multiple choice items before test administration or not? A generalizability study**

Dyrberg O'Neill, L., Radl Mortensen, S. M., Nørgaard, C., Øvrehus, A. L. H. & Friis, U. G., 18. maj 2018.

**Screening for flawed multiple choice items before test administration or not? A generalizability study**

Dyrberg O'Neill, L., Radl Mortensen, S., Nørgaard, C., Øvrehus, A. L. H. & Friis, U. G., 15. maj 2018.

**Four weeks of ledipasvir/sofosbuvir and ribavirin with or without pegylated interferon for chronic hepatitis C in non-cirrhotic people who inject drugs. A randomized trial**

Øvrehus, A. L. H., Krarup, H., Birkemose, I., Holm, D. K., Mössner, B., Ernst, A. & Christensen, P. B., apr. 2018, I: *Journal of Hepatology*. 68, 4, s. 840-842

**Screening for flawed multiple choice items before test administration or not? A generalizability study.**

Dyhrberg O'Neill, L., Radl Mortensen, S., Nørgaard, C., Øvrehus, A. L. H. & Friis, U. G., 16. mar. 2018. 3 s.

**Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe**

Fraser, H., Martin, N. K., Brummer-Korvenkontio, H., Carrieri, P., Dalgard, O., Dillon, J., Goldberg, D., Hutchinson, S., Jauffret-Roustide, M., Kåberg, M., Matser, A. A., Maticič, M., Midgard, H., Mravcik, V., Øvrehus, A., Prins, M., Reimer, J., Robaey, G., Schulte, B. & van Santen, D. K. & 3 flere, Zimmermann, R., Vickerman, P. & Hickman, M., mar. 2018, I: *Journal of Hepatology*. 68, 3, s. 402-411

**Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe**

Marshall, A. D., Cunningham, E. B., Nielsen, S., Aghemo, A., Alho, H., Backmund, M., Bruggmann, P., Dalgard, O., Seguin-Devaux, C., Flisiak, R., Foster, G. R., Gheorghe, L., Goldberg, D., Goulis, I., Hickman, M., Hoffmann, P., Jancorien, L., Jarcuska, P., Kåberg, M. & Kostrikis, L. G. & 22 flere, Makara, M., Maimets, M., Marinho, R. T., Maticič, M., Norris, S., Ólafsson, S., Øvrehus, A., Pawlotsky, J.-M., Pocock, J., Robaey, G., Roncero, C., Simonova, M., Sperl, J., Tait, M., Tolmane, I., Tomaselli, S., van der Valk, M., Vince, A., Dore, G. J., Lazarus, J. V., Grebely, J. & International Network on Hepatitis in Substance Users (INHSU), feb. 2018, I: *The Lancet Gastroenterology & Hepatology*. 3, 2, s. 125-133

**Late Presentation for Care Among Patients With Chronic Hepatitis C: Prevalence and Risk Factors**

Hansen, J. F., Hallager, S., Øvrehus, A., Weis, N., Brehm Christensen, P. & Pedersen, C., 1. jan. 2018, I: *Open Forum Infectious Diseases*. 5, 1, 3 s., ofx257.

**Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study**

Øvrehus, A. L. H. (Medlem af forfattergruppering) & European Union HCV Collaborators, 1. maj 2017, I: *The Lancet Gastroenterology & Hepatology*. 2, 5, s. 325-336

**Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study**

Christensen, P. B. (Medlem af forfattergruppering), Øvrehus, A. L. H. (Medlem af forfattergruppering) & The Polaris observatory HCV collaborators, 1. mar. 2017, I: *The Lancet Gastroenterology & Hepatology*. 2, 3, s. 161-176

**Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections: A Scandinavian real-life study**

Dalgard, O., Weiland, O., Norberg, G., Karlsen, L., Heggelund, L., Färkkilä, M., Balslev, U., Belard, E., Øvrehus, A., Skalskøj Kjær, M., Krarup, H., Thorup Røge, B., Hallager, S., Madsen, L. G., Lund Laursen, A., Lagging, M. & Weis, N., 2017, I: *PLOS ONE*. 12, 7, 8 s., e0179764.

**Four weeks of sofosbuvir, ledipasvir and ribavirin with or without interferon give high cure rates in drug users with hepatitis C - a randomized controlled trial (4WIDUC)**

Holm, A. L. & Holm, D. K., 2016.

**Hepatitis C og stof(mis)brugere – udfordringer og nye muligheder**

Holm, A. L. & Christensen, P. B., 2016, I: *Best Practice Nordic*.

**Highlights fra INHSU**

Christensen, P. B., Lazarus, J. V. & Holm, A. L., 2016, I: *Best Practice Nordic*.

**Two cases of erythema induratum of Bazin - a rare cutaneous manifestation of tuberculosis**

von Huth, S., Øvrehus, A. L., Lindahl, K. H. & Johansen, I. S., 7. aug. 2015, I: *International Journal of Infectious Diseases*. 38, September, s. 121-124

**PRESCRIPTION OF BLOOD COMPONENTS: IMPACT OF A NEW MANDATORY E-LEARNING PROGRAM FOR CLINICIANS**

Andersen, M., Holm, A. L., Titlestad, K. & Lillevang, S. T., 27. jun. 2015.

**Impact of Prioritizing Treatment in a High Resource Setting: Minimizing the Burden of HCV Related Disease in 15 Years**  
Ovrehus, A. L. H., Blach, S., Christensen, P. B., Gerstoft, J., Weis, N., Krarup, H., Clausen, M. R. & Razavi, H., 2015, I: *Journal of Hepatology*. 62, S2, s. S591-1 s., P0714.

#### **Schistosomiasis-induced squamous cell bladder carcinoma in an HIV-infected patient**

Marbjerg, L. H., Øvrehus, A. L. H. & Johansen, I. S., 2015, I: *International Journal of Infectious Diseases*. 40, s. 113-115

#### **Strategies to manage hepatitis C virus (HCV) disease burden**

Wedemeyer, H., Duberg, A. S., Buti, M., Rosenberg, W. M., Frankova, S., Esmat, G., Örmeci, N., Van Vlierberghe, H., Gschwantler, M., Akarca, U., Aleman, S., Balik, I., Berg, T., Bihl, F., Bilodeau, M., Blasco, A. J., Brandão Mello, C. E., Bruggmann, P., Calinas, F. & Calleja, J. L. & 73 flere, Cheinquer, H., Christensen, P. B., Clausen, M., Coelho, H. S. M., Cornberg, M., Cramp, M. E., Dore, G. J., Doss, W., El-Sayed, M. H., Ergör, G., Estes, C., Falconer, K., Félix, J., Ferraz, M. L. G., Ferreira, P. R., García-Samaniego, J., Gerstoft, J., Giria, J. A., Gonçalves, F. L., Guimarães Pessôa, M., Hézode, C., Hindman, S. J., Hofer, H., Husa, P., Idilman, R., Kåberg, M., Kaita, K. D. E., Kautz, A., Kaymakoglu, S., Kraiden, M., Krarup, H., Laleman, W., Lavanchy, D., Lázaro, P., Marinho, R. T., Marotta, P., Mauss, S., Mendes Correa, M. C., Moreno, C., Müllhaupt, B., Myers, R. P., Nemecek, V., Øvrehus, A. L., Parkes, J., Peltekian, K. M., Ramji, A., Razavi, H., Reis, N., Roberts, S. K., Roudot-Thoraval, F., Ryder, S. D., Sarmiento-Castro, R., Sarrazin, C., Semela, D., Sherman, M., Shiha, G. E., Sperl, J., Stärkel, P., Stauber, R. E., Thompson, A. J., Urbanek, P., Van Damme, P., van Thiel, I., Vandijck, D., Vogel, W., Waked, I., Weis, N., Wiegand, J., Yosry, A., Zekry, A., Negro, F., Sievert, W. & Gower, E., maj 2014, I: *Journal of Viral Hepatitis*. 21, Suppl 1, s. 60-89 30 s.

#### **The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm**

Razavi, H., Waked, I., Sarrazin, C., Myers, R. P., Idilman, R., Calinas, F., Vogel, W., Mendes Correa, M. C., Hézode, C., Lázaro, P., Akarca, U., Aleman, S., Balik, I., Berg, T., Bihl, F., Bilodeau, M., Blasco, A. J., Brandão Mello, C. E., Bruggmann, P. & Buti, M. & 75 flere, Calleja, J. L., Cheinquer, H., Christensen, P. B., Clausen, M., Coelho, H. S. M., Cramp, M. E., Dore, G. J., Doss, W., Duberg, A. S., El-Sayed, M. H., Ergör, G., Esmat, G., Falconer, K., Félix, J., Ferraz, M. L. G., Ferreira, P. R., Frankova, S., García-Samaniego, J., Gerstoft, J., Giria, J. A., Gonçalves, F. L., Gower, E., Gschwantler, M., Guimarães Pessôa, M., Hindman, S. J., Hofer, H., Husa, P., Kåberg, M., Kaita, K. D. E., Kautz, A., Kaymakoglu, S., Kraiden, M., Krarup, H., Laleman, W., Lavanchy, D., Marinho, R. T., Marotta, P., Mauss, S., Moreno, C., Murphy, K., Negro, F., Nemecek, V., Örmeci, N., Holm, A. L., Parkes, J., Pasini, K., Peltekian, K. M., Ramji, A., Reis, N., Roberts, S. K., Rosenberg, W. M., Roudot-Thoraval, F., Ryder, S. D., Sarmiento-Castro, R., Semela, D., Sherman, M., Shiha, G. E., Sievert, W., Sperl, J., Stärkel, P., Stauber, R. E., Thompson, A. J., Urbanek, P., Van Damme, P., van Thiel, I., Van Vlierberghe, H., Vandijck, D., Wedemeyer, H., Weis, N., Wiegand, J., Yosry, A., Zekry, A., Cornberg, M., Müllhaupt, B. & Estes, C., maj 2014, I: *Journal of Viral Hepatitis*. 21, Suppl 1, s. 34-59 26 s.

#### **Historical epidemiology of hepatitis C virus (HCV) in selected countries**

Bruggmann, P., Øvrehus, A. L., Moreno, C., Brandão Mello, C. E., Roudot-Thoraval, F., Marinho, R. T., Sherman, M., Ryder, S. D., Sperl, J., Akarca, U., Balik, I., Bihl, F., Bilodeau, M., Blasco, A. J., Buti, M., Calinas, F., Calleja, J. L., Cheinquer, H., Christensen, P. B. & Clausen, M. & 72 flere, Coelho, H. S. M., Cornberg, M., Cramp, M. E., Dore, G. J., Doss, W., Duberg, A. S., El-Sayed, M. H., Ergör, G., Esmat, G., Estes, C., Falconer, K., Félix, J., Ferraz, M. L. G., Ferreira, P. R., Frankova, S., García-Samaniego, J., Gerstoft, J., Giria, J. A., Gonçalves, F. L., Gower, E., Gschwantler, M., Guimarães Pessôa, M., Hézode, C., Hofer, H., Husa, P., Idilman, R., Kåberg, M., Kaita, K. D. E., Kautz, A., Kaymakoglu, S., Kraiden, M., Krarup, H., Laleman, W., Lavanchy, D., Lázaro, P., Marotta, P., Mauss, S., Mendes Correa, M. C., Müllhaupt, B., Myers, R. P., Negro, F., Nemecek, V., Örmeci, N., Parkes, J., Peltekian, K. M., Ramji, A., Razavi, H., Reis, N., Roberts, S. K., Rosenberg, W. M., Sarmiento-Castro, R., Sarrazin, C., Semela, D., Shiha, G. E., Sievert, W., Stärkel, P., Stauber, R. E., Thompson, A. J., Urbanek, P., van Thiel, I., Van Vlierberghe, H., Vandijck, D., Vogel, W., Waked, I., Wedemeyer, H., Weis, N., Wiegand, J., Yosry, A., Zekry, A., Van Damme, P., Aleman, S. & Hindman, S. J., 2014, I: *Journal of Viral Hepatitis*. 21, Suppl 1, s. 5-33

#### **Comparison of the medical students' perceived self-efficacy and the evaluation of the observers and patients**

Ammentorp, J., Thomsen, J. L., Jarbøl, D. E., Holst, R., Holm Øvrehus, A. L. & Kofoed, P.-E., 2013, I: *BMC Medical Education*. 13, 1, 6 s., 49.

#### **Evaluation of a comprehensive admission programme including GPA, MCQ and MMI in a large scale setting**

Holm, A. L., Vonsild, M. C., Gerstrøm, K., Jensen, M. & Wallstedt, B., 2013, *AMEE conference 2013*.

**Implementering af en ny optagelsesprocedure til medicin på Syddansk Universitet: Status på to års erfaring med uniTEST og MMI**

Jensen, M., Øvrehus, A. L., Kvist, K. G., Wallstedt, B. & Wallstedt, B., nov. 2010. 1 s.

**Implementation of a new admissions process at USD for medicine: Status on two years of experience with UniTEST and the MMI**

Jensen, M., Øvrehus, A. L. H., Kvist, K. G. & Wallstedt, B., sep. 2010.

**Objective structured clinical examination: en etableret metode til at prøve lægelige kliniske færdigheder**

Holm, A. L. & Aspegren, K., 17. maj 2004, I: Ugeskrift for Læger. 166, 21